Carfilzomib is under clinical development by Amgen and currently in Phase III for Multiple Myeloma (Kahler Disease). According to GlobalData, Phase III drugs for Multiple Myeloma (Kahler Disease) have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Carfilzomib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Carfilzomib overview

Carfilzomib (Kyprolis) is an antineoplastic agent. It is formulated as Lyophilized powder for solution and solution for intravenous/ intravenous drip route of administration. Carfilzomib is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Kyprolis is also used in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. Kyprolis in combination with daratumumab and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.

Carfilzomib is under development for the treatment of newly diagnosed primary plasma cell leukemia, kidney, amyloidosis, hematological malignancies including lymphoma, T-Cell lymphomas, relapsed or refractory peripheral T-cell lymphoma, and T-cell acute lymphoblastic leukemia, cutaneous T-cell lymphoma, Waldenstrom Macroglobulinemia, relapsed/refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma (DLBCL). It was also under development for Hodgkin's disease, kidney transplant rejection, relapsed/refractory acute myeloid leukemia, lung transplantation, refractory renal cell carcinoma, castration-resistant prostate cancer (who have previously received chemotherapy and androgen inhibitors), ovarian cancer, small-cell lung cancer, non-small cell lung cancer, relapsed/refractory mantle cell lymphoma, chronic lymphocytic leukemia (CLL), marginal zone B-cell lymphoma, neuroendocrine cancer and chronic graft versus host disease.

Amgen overview

Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines for the treatment of cardiovascular conditions, oncology/hematology, inflammation, bone health, neurological disorders and nephrology conditions. The company analyzes the difficulties of disease and understands the fundamentals of human biology to develop products harnessing advanced human genetics. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels and through partnerships with other companies. The company has a presence in Asia Pacific, Europe, the Middle East, the Americas and Australia. Amgen is headquartered in Thousand Oaks, California, the US.

For a complete picture of Carfilzomib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.